Research programme: inflammatory disease therapeutics - Janssen/Second Genome

Drug Profile

Research programme: inflammatory disease therapeutics - Janssen/Second Genome

Alternative Names: SG-2-0776

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Biotech; Second Genome
  • Developer Janssen Biotech; Mayo Clinic; Second Genome
  • Class Peptides; Small molecules
  • Mechanism of Action Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Inflammatory bowel diseases
  • No development reported Ulcerative colitis

Most Recent Events

  • 05 Mar 2018 Second Genome plans a phase I trial in Inflammatory bowel disease in 2018
  • 16 Jul 2016 No recent reports of development identified for research development in Ulcerative-colitis in USA
  • 07 Oct 2014 Second Genome enters into a collaboration with Mayo Clinic Center to support development of therapeutics for multiple disease indications, including inflammatory bowel disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top